Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Epidemiology of ovarian cancer: a review.

Reid BM, Permuth JB, Sellers TA.

Cancer Biol Med. 2017 Feb;14(1):9-32. doi: 10.20892/j.issn.2095-3941.2016.0084.

2.

Sex hormones and the risk of keratinocyte cancers among women in the United States: A population-based case-control study.

Kuklinski LF, Zens MS, Perry AE, Gossai A, Nelson HH, Karagas MR.

Int J Cancer. 2016 Jul 15;139(2):300-9. doi: 10.1002/ijc.30072. Epub 2016 Apr 15.

3.

Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea.

Park B, Park S, Shin HR, Shin A, Yeo Y, Choi JY, Jung KW, Kim BG, Kim YM, Noh DY, Ahn SH, Kim JW, Kang S, Kim JH, Kim TJ, Kang D, Yoo KY, Park SK.

BMC Cancer. 2016 Jan 6;16:5. doi: 10.1186/s12885-015-2040-0. Erratum in: BMC Cancer. 2016;16:181.

4.

Ready-to-Eat Cereal Consumption with Total and Cause-Specific Mortality: Prospective Analysis of 367,442 Individuals.

Xu M, Huang T, Lee AW, Qi L, Cho S.

J Am Coll Nutr. 2016;35(3):217-23. doi: 10.1080/07315724.2014.971193. Epub 2015 Nov 23.

5.

Menopausal hormone therapy and ovarian cancer.

Baber R.

J Midlife Health. 2015 Jul-Sep;6(3):101-3. doi: 10.4103/0976-7800.165587. No abstract available.

6.

Consumption of whole grains and cereal fiber and total and cause-specific mortality: prospective analysis of 367,442 individuals.

Huang T, Xu M, Lee A, Cho S, Qi L.

BMC Med. 2015 Mar 24;13:59. doi: 10.1186/s12916-015-0294-7. Erratum in: BMC Med. 2015;13:85.

7.

Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.

Adachi M, Banno K, Yanokura M, Iida M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Ueki A, Hirasawa A, Tominaga E, Aoki D.

Mol Clin Oncol. 2015 Mar;3(2):267-273. Epub 2014 Nov 20.

8.

A mathematical model of bimodal epigenetic control of miR-193a in ovarian cancer stem cells.

Cheng FH, Aguda BD, Tsai JC, Kochańczyk M, Lin JM, Chen GC, Lai HC, Nephew KP, Hwang TW, Chan MW.

PLoS One. 2014 Dec 29;9(12):e116050. doi: 10.1371/journal.pone.0116050. eCollection 2014.

9.

Ovarian cancer mortality among women aged 40-79 years in relation to reproductive factors and body mass index: latest evidence from the Japan Collaborative Cohort study.

Khan MM, Khan A, Nojima M, Suzuki S, Fujino Y, Tokudome S, Tamakoshi K, Mori M, Tamakoshi A.

J Gynecol Oncol. 2013 Jul;24(3):249-57. doi: 10.3802/jgo.2013.24.3.249. Epub 2013 Jul 4.

10.

Efficacy and side effects of chinese herbal medicine for menopausal symptoms: a critical review.

Xu LW, Jia M, Salchow R, Kentsch M, Cui XJ, Deng HY, Sun ZJ, Kluwe L.

Evid Based Complement Alternat Med. 2012;2012:568106. doi: 10.1155/2012/568106. Epub 2013 Jan 13.

11.

Reproductive factors and menopausal hormone therapy and bladder cancer risk in the NIH-AARP Diet and Health Study.

Daugherty SE, Lacey JV Jr, Pfeiffer RM, Park Y, Hoover RN, Silverman DT.

Int J Cancer. 2013 Jul 15;133(2):462-72. doi: 10.1002/ijc.28022. Epub 2013 Feb 12.

12.

Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer.

Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, Jacquard C, Pillon A, Balaguer P, Balabanian K, Lazennec G.

PLoS One. 2012;7(9):e44787. doi: 10.1371/journal.pone.0044787. Epub 2012 Sep 6. Erratum in: PLoS One. 2013;8(5). doi:10.1371/annotation/480acc26-456b-4e06-8cb6-2834bd6f5553.

13.

Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study.

Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, Park Y, Brinton LA.

Br J Cancer. 2012 Sep 25;107(7):1181-7. doi: 10.1038/bjc.2012.397. Epub 2012 Aug 28.

14.

The 2012 hormone therapy position statement of: The North American Menopause Society.

North American Menopause Society.

Menopause. 2012 Mar;19(3):257-71. doi: 10.1097/gme.0b013e31824b970a.

15.

Chinese herb mix Tiáo-Gēng-Tāng possesses antiaging and antioxidative effects and upregulates expression of estrogen receptors alpha and beta in ovariectomized rats.

Xu LW, Kluwe L, Zhang TT, Li SN, Mou YY, Sang Z, Ma J, Lu X, Sun ZJ.

BMC Complement Altern Med. 2011 Dec 30;11:137. doi: 10.1186/1472-6882-11-137.

16.

Body size and the risk of ovarian cancer by hormone therapy use in the California Teachers Study cohort.

Canchola AJ, Chang ET, Bernstein L, Largent JA, Reynolds P, Deapen D, Henderson KD, Ursin G, Horn-Ross PL.

Cancer Causes Control. 2010 Dec;21(12):2241-8. doi: 10.1007/s10552-010-9647-x. Epub 2010 Oct 6.

17.

Bone fractures and incident epithelial ovarian cancer in a prospective cohort study.

Danforth KN, Schairer C, Schatzkin A, Lacey JV.

J Womens Health (Larchmt). 2009 Nov;18(11):1777-82. doi: 10.1089/jwh.2008.1341.

18.

Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort.

Morton LM, Wang SS, Richesson DA, Schatzkin A, Hollenbeck AR, Lacey JV Jr.

Int J Cancer. 2009 Jun 1;124(11):2737-43. doi: 10.1002/ijc.24248.

19.

Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases.

Ting AY, Kimler BF, Fabian CJ, Petroff BK.

Cancer Prev Res (Phila). 2008 Dec;1(7):546-53. doi: 10.1158/1940-6207.CAPR-08-0015.

20.

Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.

Pearce CL, Chung K, Pike MC, Wu AH.

Cancer. 2009 Feb 1;115(3):531-9. doi: 10.1002/cncr.23956. Review.

Supplemental Content

Support Center